The aims of this study were to standardize a highly sensitive methodology of digital PCR (dPCR) to accurately identify hotspot mutations in BRAF, NRAS, and TERT in plasma and interrogate its feasibility as a liquid biopsy tool for melanoma patients. The gene discussed is BRAF; the disease is melanoma.